Dalbavancin

Mechanism :

Dalbavancin is a lipoglycopeptide which binds to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, preventing cross-linking and interfering with cell wall synthesis. It is bactericidal in vitro against Staphylococcus aureus and Streptococcus pyogenes.

Indication :

Acute bacterial skin and skin structure infections due to gram positive organisms

Contraindications :

Hypersensitivity to dalbavancin or any component of the formulation.

Dosing :

Safety and efficacy not established in pediatric population.

Adults:

1 dose regime of 1500 mg IV or give 1000 mg IV in 2 doses followed by 500 mg after 1 week.

Adverse Effect :

Flushing, headache, skin rash, hypoglycaemia, increased GGT, nausea, diarrhea, GIT haemorrhage, acute post-hemorrhagic anemia, hepatotoxicity, increased serum alkaline phosphatase, anaphylactoid reaction, infusion related reaction including red-man syndrome.

Interaction :

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol.
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.

Hepatic Dose :

Use with caution in moderate to severe hepatic impairment.